(Q34272602)

1 August 2017

title

Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease (English)

1 reference

1 August 2017

1 reference

1 reference

4

David Oakes

1 reference

1 August 2017

Katrina L Paumier

1

1 reference

1 August 2017

Andrew D Siderowf

2

1 reference

1 August 2017

Peggy Auinger

3

1 reference

1 August 2017

Lalitha Madhavan

5

1 reference

1 August 2017

Alberto J Espay

6

1 reference

1 August 2017

Fredy J Revilla

7

1 reference

1 August 2017

Timothy J Collier

8

1 reference

1 August 2017

Parkinson Study Group Genetics Epidemiology Working Group

9

1 reference

1 August 2017

language of work or name

English

0 references

publication date

3 May 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

27

1 reference

1 August 2017

issue

7

1 reference

1 August 2017

page(s)

880-887

1 reference

An estimate of the incidence of depression in idiopathic Parkinson's disease.

1 August 2017

cites work

1 reference

Prevalence, etiology, and treatment of depression in Parkinson's disease

21 January 2018

1 reference

The effect of depression on motor function and disease severity of Parkinson's disease.

21 January 2018

1 reference

The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model

21 January 2018

1 reference

Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat.

21 January 2018

1 reference

Antidepressant drugs diversely affect autophagy pathways in astrocytes and neurons--dissociation from cholesterol homeostasis

21 January 2018

1 reference

Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs

21 January 2018

1 reference

Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity

21 January 2018

1 reference

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

21 January 2018

1 reference

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

21 January 2018

1 reference

Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings

21 January 2018

1 reference

Development and validation of a geriatric depression screening scale: a preliminary report

21 January 2018

1 reference

An Inventory for Measuring Depression

21 January 2018

1 reference

The effects of antidepressants in Parkinson's disease: a meta-analysis

21 January 2018

1 reference

A controlled trial of antidepressants in patients with Parkinson disease and depression

21 January 2018

1 reference

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Antidepressant treatment restores brain-derived neurotrophic factor serum levels and ameliorates motor function in Parkinson disease patients

21 January 2018

1 reference

Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease

21 January 2018

1 reference

Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus.

21 January 2018

1 reference

Amitriptyline-mediated cognitive enhancement in aged 3×Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity

21 January 2018

1 reference

Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.

21 January 2018

1 reference

The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease

21 January 2018

1 reference

The impact of depressive symptoms in early Parkinson disease

21 January 2018

1 reference

Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes

21 January 2018

1 reference

The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations

21 January 2018

1 reference

UPDRS activity of daily living score as a marker of Parkinson's disease progression

21 January 2018

1 reference

Comparative responsiveness of Parkinson's disease scales to change over time.

21 January 2018

1 reference

The natural history of Parkinson's disease

21 January 2018

1 reference

Quality of life and depression in Parkinson's disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.24978

1 reference

1 August 2017

1 reference